Ease Labs: Brazilian laboratory specialized in cannabis stands out in pharmacies across the country

The Ease Labs, founded in Minas Gerais in 2018, focuses on the production of cannabis-based products in Brazil and has already established itself as one of the leading companies in the sector. In the first half of 2024, according to data from Close Up, the company saw its line of isolated cannabidiol (CBD) reach second place in revenue in the market regulated by RDC 327, which governs the commercialization of these products in pharmacies. This milestone positions the company as one of the main players in the supply of medicinal cannabis in the country, consolidating its presence in a market that has grown exponentially in recent years.

According to Kaya Mind, a market intelligence company specialized in cannabis, the medicinal sector of the plant in Brazil generated around R$1 billion in 2023, with expectations of annual growth exceeding 30% until 2025. Another survey conducted by Hiria shows that the Brazilian cannabis market could still reach R$ 45 billion in the next 8 years.

Within this scenario, Ease Labs has stood out for its ability to meet the growing demand for cannabis-based products, especially in the public health system. In 2024, the pharmaceutical company participated in an important bidding process in the state of São Paulo, which established it as the official manufacturer of cannabis products for the State's SUS. This expanded its reach, ensuring that thousands of patients have access to innovative and effective treatments through its therapeutic solutions.

Commitment to accessibility, quality, and safety

One of the main factors driving Ease Labs' success in the market is its unwavering commitment to the accessibility, quality, and safety of its products. The company follows all regulations established by the National Health Surveillance Agency (Anvisa), ensuring that its products undergo rigorous control and validation processes at every stage of production. From seed selection, extraction of cannabis compounds, to final manufacturing, each batch is tested in certified laboratories, ensuring standardization and quality of the products. This attention to detail has allowed them to gain the trust of both patients and healthcare professionals.

Check out the video report below that shows the behind-the-scenes of Ease Labs and the manufacturing process of its cannabis-based products

The line of isolated CBD, which has been distributed by the SUS, is a result of these commitments. This product has proven to be highly effective in treating various conditions, including refractory epilepsies such as Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis, pathologies covered by the SP Law.

Expansion and impact on the market

With more mature regulations on the commercialization of cannabis products in pharmacies since the RDC 327, approved in 2019, the Brazilian market has become one of the most promising in Latin America. Today, over 400,000 patients use cannabis-based treatments in Brazil, and this number is expected to grow as regulations advance and access to products becomes easier.

The victory in the bidding process in São Paulo was an important step for Ease Labs. As the official supplier of cannabis medications in the São Paulo SUS, the company began to operate directly in Brazil's largest public health system, allowing its products to reach patients who previously had no access to cannabis-based therapies. This move not only increased the company's market share but also reinforced its commitment to accessibility and inclusion.

Additionally, Ease Labs has been preparing to increase its production capacity and expand its product portfolio, which, according to the company, has been seeking new medicinal compounds beyond cannabis. To strengthen its commitment to innovation and the development of advanced therapies, the company has just formed a partnership with CERTBIO (Center for Biomaterials Reference at the Federal University of Campina Grande) to create a new medication based on psychedelic compounds.

This project, approved by the National Council for Scientific and Technological Development (CNPq), aims to explore the therapeutic potential of N,N-dimethyltryptamine (DMT), focusing especially on the treatment of major depression, a challenging condition in the field of mental health. The initiative, which originated from the Ease Labs Cannabinoid Knowledge Acceleration Program (Pacce), marks a significant advancement, expanding the company's portfolio beyond cannabis products and highlighting its commitment to offering innovative solutions for complex diseases, with the goal of transforming public health and improving the quality of life for patients.

A promising future

With the support of public policies and regulations that favor the growth of the medicinal cannabis market, Ease Labs is well positioned to continue expanding its operations in Brazil and internationally. The company's commitment to science, innovation, quality, and safety, combined with its vision of making cannabis-based treatments more accessible and effective, places it in a leadership role in the sector.

The growing demand for cannabis products, both in the private and public markets, such as the SUS, reflects the confidence of consumers and healthcare professionals in the effectiveness of these therapies. Ease Labs, with its solid regulatory and scientific foundation, has the potential to transform how cannabis treatments are perceived and utilized in Brazil, offering high-quality therapeutic solutions and a positive impact on the health of the population.